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2.
3.
4.
Content
4
5Drug policies fall within states’ responsibility, leading to a variety of 
national action plans and strategies reflecting the diversity of situations 
in the different countries. To make the most of this diversity, other 
countries’ experiences are widely discussed and taken into account. 
While there is a wish to learn about different policies and strategies 
in Europe, language continues to be a barrier since many of the 
relevant documents are not translated. An ever-increasing amount 
of documentation on evidence-related research, guidelines, manuals 
and good practice inventories is now available. At the same time, 
a significant number of international legal and political instruments 
need to be taken into account when developing and implementing 
action plans and strategies. In addition, there are various tools 
developed by international governmental and non-governmental 
bodies. However, qualified overviews allowing policy makers quickly 
to identify instruments and tools relevant to their work are rare, or even 
non-existent. The sheer quantity of available resources has grown 
to the point where giving them adequate consideration is becoming 
impossible. Furthermore, much of the material available is targeted at 
professionals and rarely at those involved in policy decisions. 
This policy paper aims to provide decision makers and policy managers 
with an overview of the basic principles, instruments and tools that will 
support them in developing, reviewing and implementing drug policies, 
strategies and action plans. It summarises key elements for coherent 
drug policies and effective strategies in the form of a series of guiding 
principles. It also lists a selection of relevant instruments, tools and 
resources proposed by European and international organisations 
(Appendix 1) and sets out a number of key observations by policy 
makers on existing practice (Appendix 2).
Scope and 
purpose
1 
6It is acknowledged that societies are finding it increasingly hard 
to deal with the phenomenon of addictions, whether dependency 
on legal and illegal drugs or licit substances, like alcohol and 
nicotine, addiction to gambling, the Internet or electronic games, 
or eating disorders. Evidence is coming to light that, with regard 
to each of these categories, the receptor and neuro-transmitter 
systems in our brains do not function differently, as the different 
policies and approaches to the different areas of addiction would 
tend to imply. This suggests that problems related to drugs need 
to be tackled in the wider context of addictions.
  
At the same time, drug trafficking and dealing can threaten 
the stability of our societies and international security. Illegal 
substances create an underground economy, which on account of 
its size poses significant threats to the official “overground” one. 
It follows that policies tackling drug abuse and trafficking in illicit 
drugs will have implications for economic and security policies. In 
addition, drug policies need to address the social consequences 
and the public health context. All policy measures must also be 
devised in the light of and in accordance with existing human 
rights standards.  
Context 
2 
7The starting point for any drug strategy or policy is an 
understanding that drugs continue to endanger public health, and 
that illicit drug trafficking constitutes a threat to safety and public 
order. In addressing these issues, the policies and measures 
adopted should reflect a shared responsibility to safeguard human 
rights and respect for the rule of law. Only by upholding these 
principles can dealing with drug abuse and illicit drug trafficking 
have sustainable effects for the benefit of society as a whole.
For drug policies to succeed and attain the desired impact, it is vital 
that the expected results and consequences should be explored 
and discussed in a wider political context, encompassing all the 
directly or indirectly relevant policy areas.
3.1. An approach based on human rights
Adopting an approach based on human rights means incorporating 
all the applicable human rights standards into drug related policies, 
strategies and action plans and their implementation processes. 
This will allow enhanced compliance with these standards and 
constitute a concrete way of safeguarding human rights. In this 
context the term human rights refers to the legal rights enshrined 
in existing instruments, e.g. the Council of Europe’s conventions.
Bringing human rights to the forefront of drug policies entails 
balancing human rights and public interests, so as to deal more 
effectively with the problems associated with psychoactive 
substances. This human-rights-based approach also makes it 
possible to address multi-dimensional problems from a global 
perspective, taking into account a range of inter-related and 
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The components 
of a drug policy
8mutually reinforcing adverse factors, while avoiding stigma, 
discrimination, insecurity and social exclusion. A drug policy 
founded on human rights considerations thus has the potential 
to be more effective in reaching vulnerable groups within society.
Ensuring and facilitating the participation of those who are 
the targets of drug policies, such as user groups and family 
members, not only constitutes good democratic practice in policy 
development, but can also make for more effective measures 
and a wider policy reach. Participation is an important source 
of empowerment and makes it possible to involve those directly 
concerned as a resource in the active search for solutions.  
3.2. The public health angle
Through public policy governments seek to look after the health, 
security and well-being of their citizens. Psychoactive substance 
use and addictions are related to physical and mental conditions, 
and in turn affect physical and mental health. But the phenomenon 
is not only a health issue. The social determinants related to 
psychoactive substance use: personality, attitudes, expectations 
and motivations of the user, as well as his or her life situation and 
social context, show that the phenomenon has overall societal 
connections. In addition, there are the related dimensions of drug-
related crime, public nuisance and security concerns, as well as 
the financial and economic consequences. As they are linked 
to physical and mental health as well as to the overall societal 
context and public security concerns, policies on psychoactive 
substances qualify as a public health issue.
Early intervention and primary prevention are crucial when 
seeking to reduce the impact of risk factors and strengthen the 
protection of a person who is vulnerable and/or at risk of starting 
drug use. This is about intervening early in life, but also at an 
early stage in cases where potential problems may be emerging. 
This means that the possible target groups are not just children 
and young people, but in fact anyone who can be considered 
vulnerable and/or at risk. Early intervention consists in identifying 
and handling a problem at such an early stage that the problem 
disappears or is reduced with limited intervention.  
93.3. Targeting vulnerable groups
There is broad consensus among member states that policies 
need to pay specific attention to groups of people considered to 
be particularly at risk and vulnerable to drug use. These include: 
young offenders; young people in care; early school leavers 
or students with academic problems; young people who live in 
disadvantaged families or neighbourhoods; clubbers; people 
generally at risk of social exclusion and marginalised groups. 
Special attention must be paid to children of families with addiction 
problems and people traumatised by violence or sexual abuse. 
Research shows that people in these groups have a higher risk of 
early drug use, and faster progression to problem drug use, than 
people in the social mainstream.
To achieve maximum effectiveness in reducing the risk that drug 
use related problems will arise, and tackle these problems where 
they are most likely to occur, drug policies should give priority to 
reaching these vulnerable groups. Key factors in achieving this 
are ensuring adequate access to services, on the one hand, and 
taking selective, target action, on the other.
3.4. Evidence-informed policy approaches
Evidence-informed policies and practices are those which make 
the best use of the evidence available to formulate policies and 
obtain indications on how they can be successfully implemented. 
The available evidence can provide an understanding as to which 
existing measures have proven effective or, conversely, have 
shown little or no effect. However, with regard to some issues 
the evidence base is limited, and on other issues the evidence 
may raise more questions than it offers answers.  Consequently, 
in those areas where sufficient evidence is available, it should 
be used for the formulation of priorities. In areas where there is 
little or no evidence, experimentation should be encouraged and 
ethics-based approaches should be followed.
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Practical mechanisms for linking policy and research are 
indispensable to allow a systematic review of existing evidence 
so as to form a better understanding of how it might be interpreted 
and applied.  This does not require the creation of new structures 
or institutions. It primarily entails multiplying the points and 
occasions where research and policy already meet and interact: 
advisory groups, policy reviews, evaluations, policy briefings, 
training and further education. Such interface mechanisms 
between policy and research can review and process research 
findings and available evidence. The relevant information has to 
be synthesised and formulated in a way that answers decision 
makers’ needs.  Policy options should be outlined and the 
potential impacts, consequences and risks should be addressed. 
3.5. Coherence between policies on licit and  
       illicit drugs
Growing poly-drug use and findings from addiction research and 
neurobiology have led to more holistic approaches in dealing with 
substance abuse. The fact that often substance abuse and other 
addictions are interrelated calls for coherence and consistency 
between policies dealing with licit and illicit drugs, as well as those 
dealing with other forms of addiction and dependency, notably 
addiction to medicines, gambling or Internet use. As a result, public 
health and increasingly ‘well-being’ are becoming the overarching 
starting point for policy approaches that embrace both licit and 
illicit substances in an attempt to achieve more comprehensive 
responses. This can also help to ensure that policy measures in 
one field do not counteract policy goals in another.
The concept of ‘coherence’ in relation to illegal and legal 
psychoactive substances may serve as a basis for a national 
drug policy that takes into account how the various social and 
political problems connected to the use and abuse of different 
psychoactive substances are interrelated and interact. Drug 
policy is more than a set of laws and programmes; it requires 
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consistency between policy elements. It must take into account 
the interaction of drug policy with other areas: economic policy, 
employment policy, family policy, youth policy, etc. in order to 
be effective and have a broad impact. Non-observance of such 
contextual factors will generate risks that well-intended policies 
in one field may lead to inconsistency with policy goals in other 
fields, or even create adverse effects.
3.6. Balanced approach between demand    
       reduction and supply reduction
Today all the relevant legal and policy instruments state that drug 
policies aim to strike a balance between supply reduction efforts 
and demand reduction measures. In this connection, it is important 
that this balance should be adequately reflected in budgetary 
allocations and the setting of priorities. For a balanced approach 
to function effectively, coordination and cooperation between the 
two sectors must be ensured. In the field of drug policies it is of 
particular importance that law enforcement agencies cooperate 
effectively with social and health services and that these two 
spheres complement each other in their work. 
3.7. Supply reduction
Supply reduction is law enforcement and traditionally encom-
passes the interception and seizure of drugs, disruption of drug 
markets and cooperation between law enforcement, border con-
trol and customs agencies at the national and international levels. 
Combating money laundering and fighting corruption are of equal 
importance for an effective drug supply reduction strategy. 
For licit psychoactive substances regulatory measures such as 
licensing systems, age limits and distribution control systems, as 
well as the control of synthetic drugs and licit chemical precursor 
products for the production of illicit substances, constitute 
indispensable tools for any coherent supply reduction strategy. 
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To be effective in terms of deterrence and at the same time 
provide a means of drying up the financial resources for illegal 
drug transactions, criminal justice systems need to offer effective 
means of seizing proceeds, profits and assets from illegal 
trafficking and dealing of drugs, as well as sanctions for networks 
and institutions that facilitate such transactions.  
In the context of globalised drug trafficking, effective transnational 
cooperation among front-line stakeholders is vital. Policies must 
take account of the need for direct, real-time communication 
between relevant law enforcement, border control and customs 
agencies to effectively implement trans-frontier cooperation. 
Hence the importance of facilitating the necessary technical 
infrastructure and training for all levels of transnational inter-
agency cooperation. 
With a view to intercepting drug trafficking, much attention has 
been paid to the key means of transportation and channels used 
by traffickers. Observations concerning changes in trafficking 
patterns show the need for a growing focus on general aviation 
and small airfields, as well as small sea ports and isolated coastal 
regions. A further challenge in supply reduction and risk control is 
countering the sale of psychoactive substances via the Internet.
Developing indicators to gauge the effectiveness of supply 
reduction measures is of primary importance. The use of such 
indicators facilitates the setting of supply reduction objectives and 
the measurement of interventions’ success. Evaluating the overall 
effectiveness of interventions is a prerequisite if supply reduction 
policies are to be efficient and cost effective.
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3.8. Demand reduction
While all supply reduction measures have a preventive scope 
and purpose, preventive measures to reduce demand are of 
equal importance. Demand reduction is commonly understood to 
encompass prevention, treatment, rehabilitation and addressing 
the risks and adverse effects of drug use. 
3.8.1. Prevention
It has to be recognised that obtaining evidence as to what 
works in prevention, and with a view to differentiating between 
correlation and causation of an intervention, will continue to be 
difficult. Nevertheless it is important to have a prevention strategy 
that incorporates concepts and models that have been tried in 
practice and have produced promising results. 
Any prevention strategy should include elements of universal, 
selective and indicated prevention. Prevention should encompass 
programmes addressing young people, as well as adults. The 
appropriateness and feasibility of each of these prevention areas 
should be carefully assessed with regard to the specific situations 
encountered in a country. Based on this assessment the focus of 
the prevention strategy should be decided so as to make best use 
of resources and achieve the highest possible degree of impact. 
Universal prevention strategies address the entire population. 
The aim is to deter people from beginning use or to delay the 
onset of substance abuse by giving everyone the information and 
skills needed to prevent the problem from occurring. 
Selective prevention targets specific sub-population groups whose 
risk of developing a disorder is significantly higher than average, 
either imminently or over the lifetime of the individuals concerned. 
A primary advantage of focusing on vulnerable populations is that 
they are clearly identifiable and have known characteristics that 
permit targeted action aimed at preventing the initiation of drug 
use or delaying onset. 
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Indicated prevention aims to identify individuals who exhibit 
indicators that are highly correlated with an individual risk of 
developing substance abuse later in life or show early signs of 
problematic substance use. The aim of indicated prevention 
efforts is to prevent the development of substance dependence.
To allow early detection and make possible appropriate 
interventions in respect of at risk and vulnerable groups it is 
necessary to engage, sensitise and, where needed, train GPs 
and other actors of the primary health care sector, as well as 
protagonists in other sectors such as child care and education. 
3.8.2. Treatment and rehabilitation
Treatment policies should be based on integrated treatment 
systems that enable abstinence, maintenance and services aimed 
at reducing drug-related harm to work together in a continuum of 
care. These should be closely connected with services aimed at 
reducing the adverse effects of drug use in order to provide a 
comprehensive care and support system. On the one hand, this 
includes easily accessible low threshold services that meet the 
immediate needs of drug users, as well as incentives and support 
with a view to motivating drug users to abandon drug-using 
lifestyles. On the other hand, concrete pathways into structured 
treatment programmes for achieving stabilisation or abstinence 
must be put in place. The services available should be geared to 
accommodate the needs of different patient groups.
Mainstream healthcare should be engaged in screening and in 
intervening where substance abuse is beginning to develop into 
problematic use or addiction. While treatment options are often 
available to the most problematic drug users, populations that are 
on the way towards severe addiction and problematic substance 
misuse should also be given the necessary attention. 
Treatment and rehabilitation go hand in hand. Social inclusion 
measures aimed at facilitating rehabilitation are an important 
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prerequisite for successful treatment. Measures connected to 
housing, employment, leisure activities, etc. are key elements for 
successful rehabilitation. 
3.8.3. Reducing adverse effects of drug use
Measures to minimise drug-related damage, reduce deaths and 
mitigate public nuisance are an integral part of many national drug 
strategies and a clear policy priority in a majority of countries. 
Measures to minimise health risks associated with drug use 
have also proved to be an important contribution to mainstream 
public health approaches, in particular in the area of blood borne 
diseases.
Measures aimed at limiting the negative consequences that 
substance abuse entails for the user, for public health and for the 
general picture of disease have been endorsed globally by the 
United Nations and in the EU drugs strategy and action plans. 
They encompass interventions, programmes and policies that 
seek to reduce the adverse health, social and economic effects 
of drug use for individuals, communities and societies. Risk 
and harm reduction refers to the nine factors listed in the WHO/
UNAIDS/UNODC Technical Guide of 2009.
These measures take the form of intervention packages tailored 
to local contexts and needs. In order to be effective, they require 
embedding in and linking to prevention measures and treatment 
offers.  The potential impact of such measures derives from the 
combined delivery of multiple interventions.
In devising and implementing these measures, their effectiveness 
and cost-benefit ratio must be borne in mind in order to achieve 
sustainable and politically justifiable results. Furthermore, the 
measures and related services must be developed and promoted 
in such a way that they command a degree of acceptance in 
society, in particular in the communities and areas where they 
are delivered.
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3.8.4. Continuity of care
In general, drug related problems are long-term issues in every 
respect. In terms of the time needed to research the effectiveness 
of an intervention, or the time required for effective treatment and 
rehabilitation, medium and long-term commitment and support is 
needed. As a result, policies and strategies should be based on 
realism regarding time frames and an understanding of the need 
for long-term goals and perspectives.  
For treatment service provision and action aimed at reducing 
risks and the adverse effects of drug use it is important to ensure 
the continuity of availability and access. For interventions and 
treatment offers to be effective and efficient, it is of importance 
that the services provided in prisons coincide and link up with 
those provided outside the prison system. Prior investment in 
treatment can be wasted if adequate continuation of treatment is 
jeopardised by a change of setting. 
An essential prerequisite for social inclusion is continuity between 
treatment and rehabilitation aimed at ensuring effective re-
integration into society following treatment; employment, housing 
and debt restructuring are of primary importance here. It must 
be noted that treatment and rehabilitation should be facilitated in 
parallel. With certain patients rehabilitation and social reintegration 
measures can themselves lead to a reduction in consumption and 
addiction levels, thus making it possible to scale down treatment 
intensity.
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3.9. Taking into account international    
       instruments and best practice
There is a broad range of legal and political instruments that must 
be taken into account when developing drug policies. In addition 
there are a vast number of tools for different drug policy sectors 
that provide general, specific and individually targeted options.
In order to successfully develop coherent drug policies and 
allow for the complexity of these matters, without overstretching 
planning and development resources, it is essential to draw on 
existing instruments and expertise for conceptual guidance. A 
variety of instruments, tools and resources exist at the levels of 
the Council of Europe, EU, EMCDDA, UNODC, INCB, WHO and 
so on (a selection of which is listed in Appendix 1). They offer 
indispensible practical advice and tools for policy makers. 
The resources on offer range from comparative data on 
consumption, harm arising from consumption, and policy 
responses - in the areas of tobacco, alcohol and psychoactive 
drugs, addictions and public health - to data collection for framing 
comprehensive, integrated policies covering all dependence-
producing substances. The Pompidou Group provides best 
practice examples through its EXASS Network, which links 
policy with practice. The EMCDDA’s best practice portal is a 
comprehensive resource for drug policy makers in the areas of 
drug-related prevention, treatment, social reintegration and harm 
reduction.
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3.10. Transversality
Today the drug problem is perceived as multifaceted and, thus, 
politically as a transversal issue requiring action by different 
policy sectors: health, public health and social issues, law 
enforcement and border control, justice and correction systems, 
foreign affairs and international relations, as well as human rights. 
It is of the essence of multifaceted problems that they require 
multidisciplinary responses from different agencies in different 
sectors so as to deal effectively with prevention, health and social 
issues. If policies addressing such complex matters are to be 
effective they need to be founded on a comprehensive concept, 
combined with a range of measures in different policy fields.  
Coordination and cooperation between the various actors and 
agencies operating in all the sectors concerned is indispensible 
to the effective implementation of a comprehensive drug policy 
approach. It is therefore necessary that policies and strategies 
clearly recognise the need for cooperation across sectors and for 
coordination between relevant stakeholders. The drug policy and 
strategy constitute the common starting point for all stakeholders; 
they should be clear as to what role the different actors are 
expected to play.
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At every stage, whether planning, preparation or implementation, 
all possible outcomes, including negative outcomes and side-
effects of implementing measures, need to be anticipated and 
observed. Particular attention must be paid to measures that may 
trespass on the domains of other institutions and actors. Similarly 
care must be taken to ensure that outcomes do not conflict with 
or undermine other policy goals. 
Political and cultural sensitivities should be observed and 
met through an active communication and information policy 
regarding drug policy action. This also requires openness to an 
on-going dialogue with those affected or concerned by drug policy 
measures.
Consultation with civil society, notably NGOs, advocacy groups 
and commercial service providers, constitutes an important 
source of ideas, innovative proposals and potential support. At 
the same time open debate with relevant civil society actors can 
be a crucial means of dealing with conflicts emerging within the 
context of drug policy implementation. 
Effective drug policy governance requires the on-going, systematic 
review of existing and emerging evidence from science and 
practice. 
4 
Policy planning and 
implementation
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4.1. Building institutional support
Policies are implemented most effectively when they are widely 
supported. This is best achieved through consensus-building with 
all those concerned and affected, as early as the planning stage. 
However, the process of building consensus around a policy is 
difficult and complex. Little practical and theoretical guidance is 
available.  Consensus must be built between the policy sectors 
concerned, as well as between administrative and political 
structures and bodies. 
In particular, a common understanding between the political 
and the administrative levels is important to ensure that, at the 
implementation stage, coherent policies do not fall apart and 
implementation does not follow a completely different course than 
that anticipated. It is therefore advisable to ensure that policies, 
strategies and programmes are precise and clear. This means 
outlining the goals and expected results, as well as identifying 
the relevant stakeholders, what is expected of them and what 
benefits are foreseeable in return.
It is also necessary to develop conflict management procedures 
constituting an effective response to frictions and conflicts 
emerging between stakeholders. In this respect, it is of particular 
importance to put in place a mechanism that mitigates conflicts 
between the parties involved in supply reduction and demand 
reduction. 
4.2. Efficiency and effectiveness
It needs to be recalled that policy responses to drugs and drug-
related problems cannot be based solely on scientific evidence 
and efforts, but also need to take into account values, cultural 
influences, organisational structures and public opinion. It should 
also be noted that it is often complicated to make good use of 
research results because of the different concepts and terminology 
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used in the policy and science spheres. Care should be taken that 
research results are not used in a selective and over-simplified 
way, since this may negatively influence the outcome of an action 
or even lead to adverse outcomes.
Drug policy measures should always have more positive than 
negative effects. Because of limited resources action should focus 
on interventions that have proven to yield the expected results. In 
cases where proposed practices have previously not proven to be 
effective, they should be avoided or discontinued. 
In implementing the balanced policy approach it is crucial that the 
elements of supply and demand reduction are put into practice 
simultaneously. Selective, fragmented or consecutive action can 
diminish the effects of the measures implemented.
In general, multidisciplinary approaches and cooperative action 
are more effective in reaching expected results and have a broader 
impact. They can also be more resource efficient if good use is 
made of synergy effects, resources are pooled and experience of 
what works and what not is shared openly on all levels. 
4.3. Creating structures for cooperation and  
       coordination
Cooperation and coordination between the local, regional, 
national and international levels are always prerequisites for a 
successful drug policy.
Measures and actions should be designed already with a 
partnership approach in mind. Consequently potential partners 
should be involved from the planning stage or as early as possible. 
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Minimum conditions for a partnership to function and succeed 
include:
• Having a common goal 
• Ensuring regular and on-going contact
• Agreeing on communication flow 
• Ensuring direct cooperation on all levels 
• Being aware of limitations, prejudices and institutional 
cultures
• Overcoming legal barriers 
• Respecting the concept of mutuality 
There is a need for structures that ensure that actions are 
coordinated and executed in cooperation with the right partners to 
achieve a maximum impact and ensure the best use of resources. 
It is consequently important to avoid undue competition between 
participants in a cooperative effort and ensure that their activities 
and actions are complementary rather than contradictory. 
Mechanisms are also needed to increase contacts between the 
demand and supply reduction sectors, so as to arrive at concerted 
actions and avoid contradictions or adverse consequences of 
specific interventions. This does not require the setting up of new 
formal structures but first and foremost common platforms for 
regular communication, which can well be of an informal nature.
Whilst it may be difficult to achieve, it is important to understand 
that a non-hierarchical relationship between partners in the 
cooperation is one of the key factors for success. Partnerships 
built on consensus create a stronger sense of ownership and a 
higher level of commitment than those set up solely on the basis 
of legal obligations or instructions. 
When building coordination and cooperation between players 
the specificities of the national, regional and local levels must be 
observed and addressed in a balanced manner. Solutions will 
depend on the type of mechanisms regulating the cooperation 
and relations between different levels of policy responsibility. One 
way is to have an arrangement where common policy approaches 
are negotiated between entities of different levels of responsibility. 
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Providing financial incentives and targeted funding from the 
national level to regional and local authorities have proven to be 
viable means for developing policy consistency between different 
levels. 
4.4. Monitoring and evaluation
In practice evaluation is the process of developing a scientifically 
based judgment about the value of an action. Monitoring is 
the regular, systematic collection of data on a given activity as 
a basis for evaluation and input for quality control.  In addition, 
it is a general and systematic source of knowledge on what is 
done. Evaluation also constitutes an important tool for forward 
planning. From an evidence-informed perspective, monitoring 
and evaluation are important to demonstrate that interventions 
have positive effects, which outweigh any potential adverse 
consequences.
There are different compelling reasons for evaluating policies 
and their implementation. Above all, evaluation results can attest 
to success and to the legitimacy of requests for political and 
financial support. They can also provide an evidence base for 
improving the quality and effectiveness of the measures applied 
and contribute to quality control.
In general, evaluation should be done for medium and large scale 
interventions, pilot-projects and innovations. It is often not feasible 
for one-off activities or very small-scale interventions. It can be 
dispensed with where the quality and impact of an intervention 
are already known and well established. In such cases less 
complex quality assurance tools may suffice.
It has to be understood that evaluation results alone cannot 
constitute the basis for evidence-informed policies, since they 
incorporate too many administrative and political constraints. 
Nonetheless, evaluation allows the collection of data on a 
concrete drug situation and the effects of responses to it, thus 
providing valuable input for public discussion on policy choices. 
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4.5. Ensuring quality
Quality assurance can be defined as a system of procedures, 
checks, audits and corrective actions to ensure that a service 
or action delivered is of the highest achievable quality. Quality 
assurance can be implemented as a more or less formal control 
measure and with a higher or lower level of reporting through 
internal assessments or external evaluation. The most commonly 
used means and tools for ensuring quality are the setting of 
quality standards and the application of guidelines, the conduct of 
evaluations and the provision of regular staff training.
Process evaluation constitutes the most frequently applied tool 
in quality assessment. Process evaluation can be carried out at 
any time to analyse how an activity is conceptualised, planned, 
and implemented. It makes it possible to assess whether services 
and products are delivered in a qualitatively and quantitatively 
appropriate way.
Continued staff education is an important means of familiarising 
professionals with the latest developments and knowledge in 
a rapidly evolving policy field. The volume of evidence-based 
reviews, guidelines, manuals and good practice recommendations 
is steadily growing. As a result continued education and training 
for professionals working in the substance abuse field is an 
increasing focus of attention and a core component of any quality 
management initiative. 
It is important that the education provided is adequately targeted 
and that a fragmented approach is avoided. The quality of the 
education dispensed also needs to be ensured through appropriate 
standard procedures, including definition of the qualification 
profiles required for implementing the various measures.
 
25
4.6. Initiating and managing change 
Drug policies need to be reactive but also proactive in order to 
have a broad and sustainable impact. While policies have to be 
reactive to developments, it is equally important that they have 
a dynamic dimension, making it possible to anticipate future 
developments and predict change. In concrete terms this means 
that drug policies, planning, services and concepts should allow 
for a sufficient degree of flexibility and adjustment as situations 
evolve. At the same time, political decision makers, managers and 
professionals need to be adequately informed about emerging 
trends and to have appropriate links with early warning systems 
and the relevant bodies such as the PG, EMCDDA, UNODC and 
WHO.
Being alert to changes, and having the capacity to adapt to 
changes as societies and situations evolve, are indispensible 
prerequisites to ensure the credibility and efficacy of policy. 
Evolving drug scenes, new substances and emerging scientific 
insights contribute to a rapidly changing environment that drug 
policies seek to address. These dynamics must be adequately 
taken into account in every course of action so as to avoid policies 
becoming ineffective or having effects different from those initially 
envisaged. A system of feedback from the level of service delivery 
should accordingly be in put in place that makes it possible to 
alert stakeholders about changes in substance use patterns and 
new substances. Communication channels should also ensure 
that, in situations where measures do not deliver the anticipated 
effects or even have adverse consequences, the policy level is 
rapidly informed to allow for swift reactions and adjustments.
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Selected instruments, 
tools and resources 
providing guidance to 
drug policy makers
 
General drug policy development
Achievements & Results 2007 - 2010 (Pompidou Group 
P-PG /MinConf (2010) 1)
Signals and Results 2004 – 2006 (Pompidou Group P-PG/
MinConf (2006) 2)
These reports on the implementation of the PG work programmes 
between 2004 and 2010 contains relevant guidance, information 
and further references for policy makers and managers in the 
areas of prevention, treatment, criminal justice, research and 
ethics based on the findings and conclusions of the respective 
expert platform. The signals and recommendations therein reflect 
the position of experts from research and the experience of 
professionals. They are aimed to provide guidance for the political 
decision making level. The conclusion drawn by the Permanent 
Correspondents of the Pompidou Group from these results and 
findings are contained in appendix 2 of this document.  
Research and policy (Pompidou Group P-PG/RES (2009) 9) 
This report provides examples of the interaction between 
researchers and policy-makers from 16 countries prepared by 
members of the Pompidou Group’s Research Platform. 
1 Appendix
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Old and new policies, theories, research methods and drug 
users (Pompidou Group and ESSD 2009 – ISBN publication) 
This publication informs on patterns of and changes in the use 
of old and new drugs; looks at existing theories, and examines 
strategies and treatment options for imprisoned offenders. In 
addition, it offers new approaches to bridging the gap between 
quantitative and qualitative drug research.
Drugs and drug dependence: linking research, policy and 
practice, lessons learned, challenges ahead (Pompidou 
Group 2004 – ISBN publication)
This publication describes how research, policy and practice can 
be linked best when dealing with drugs and drug dependence.
 
EU drugs action plan 2009-2012
The EU drugs action plan includes wide-ranging measures 
to strengthen European cooperation to curb the adverse 
consequences of drug use and cut drug-related crime. It is 
conceived around five priorities: reducing the demand for 
drugs, mobilising European citizens, reducing supply; improving 
international cooperation, and improving understanding of the 
drugs phenomenon.
EU drugs strategy 2005-2012
Confirming the EU’s integrated, multidisciplinary and balanced 
approach to drugs combining demand and supply reduction, 
the strategy focuses on these two policy fields as well as on two 
cross-cutting themes: ‘International cooperation’ and ‘Research, 
information and evaluation’. It also emphasises the importance of 
making optimal use of existing legal and information instruments 
and the need to ensure adequate consultation with a broad 
group of partners (e.g. scientific centres, drug professionals, 
representative NGOs, civil society and local communities).
 
28
Coherent and integrated policies
Coherent drug policy: Some reflections on the concept 
of coherence in relation to a policy on psychoactive 
substances and beyond.  
(Pompidou Group, doc. P-PG-CoherPol (2011) 14 - ISBN 
publication 2012)
The study analyses the context and systems that better suit 
coherent drug policies and what models/indicators may be 
developed to better inform one of the outcome of such policies. 
Towards an integrated policy on psychoactive substances 
(Pompidou Group 2010 – ISBN publication)
This theoretical and empirical analysis builds upon the work 
of ‘From a policy on illegal drugs to a policy on psychoactive 
substances’ (2008) and presents the scientific grounds for 
choosing between a separate policy for each substance and a 
single, “integrated” policy incorporating all substances. It also 
gives examples how integrated and coherent policies can be 
implemented.
From a policy on illegal drugs to a policy on psychoactive 
substances (Pompidou Group 2008 – ISBN publication)
This study shows how drug policies and strategies are developed 
across Europe, taking into account differing contexts, the 
influence of international instruments, and the evolution of 
scientific knowledge. This work in part provides information on 
why some countries opt for an integrated policy on substances, 
and other for a separate policy for different substances.
29
Signals from drug research  
(Pompidou Group 2009 – ISBN publication)
This report provides the latest results from research in the fields 
of social sciences, psychology and biomedicine with regard to 
drug addiction and dependency of psychoactive substances. It 
is directed to policy makers and others who work with drug policy 
implementation.
Drugs and alcohol: violence and insecurity  
(Pompidou Group 2009 P-PG/CJ (2004) 7)
This guide provides information about the correlation between 
substance use, trafficking in illicit drugs and crime. It also provides 
insights on the interaction of different substances when used in 
poly drug consumption with regard to stimulating violence.
Responding to open drug scenes, drug related crime 
and public nuisance: towards a partnership approach 
(Pompidou Group P-PG/Coop (2006) 3)
The complexity of these problems requires a multi-faceted 
response developed and implemented in partnership between 
relevant agencies and stakeholders. This report provides an 
overview of integrated approaches to deal with open drug scenes, 
drug-related crime and the types of responses developed across 
the greater Europe. The content covers the experience in over 
thirty cities.
Framework Convention on Tobacco Control (WHO 2005)
The WHO Framework Convention on Tobacco Control (WHO 
FCTC) was developed in response to the globalization of the 
tobacco epidemic and is an evidence-based treaty that reaffirms 
the right of all people to the highest standard of health.
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Human Rights
Convention for the Protection of Human Rights and 
Fundamental Freedoms (Council of Europe 1951 ETS no. 5) 
• Article 2 sets out that everyone’s right to life shall be 
protected by law. 
•	 Article 3 prohibits inhuman or degrading treatment.
•	 Article 4 on prohibition of slavery and forced labour stipula-
tes under section 2 that no one shall be required to perform 
forced or compulsory labour. 
•	 Article 14 prohibits discrimination, inter alia, on the 
grounds of language, religion, national or social origin, 
association with a national minority, property, birth or other 
status.
Convention for the Protection of Individuals with regard to 
Automatic Processing of Personal Data  
(Council of Europe 1981 ETS no. 108) 
•	 Article 6 prohibits the processing of personal data con-
cerning health unless domestic law provides appropriate 
safeguards.
Convention on Human Rights and Biomedicine  
(Council of Europe 1997 ETS no. 164) 
•	 Article 1 defines the purpose of this convention as to 
protect the dignity and identity of all human beings and 
guarantee everyone, without discrimination, respect for their 
integrity and other rights and fundamental freedoms with 
regard to the application of biology and medicine.
•	 Article 2 acknowledges the primacy of the human being 
by setting out that the interests and welfare of the human 
being shall prevail over the sole interest of society or sci-
ence.
▶
▶▶
▶
▶
▶
▶
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•	 Article 3 stipulates equitable access to health care of 
appropriate quality.
•	 Article 4 requires that any intervention in the health field, 
including research, must be carried out in accordance with 
relevant professional obligations and standards.
•	 Article 5 sets out that intervention in the health field may 
only be carried out after the person concerned has given 
free and informed consent to it and that appropriate 
information as to the purpose, risks and consequences of 
an intervention is given. The person concerned may freely 
withdraw consent at any time.
•	 Article 10 defines in section 1. that everyone has the right 
to respect for private life in relation to information about 
his or her health. Section 2 provides the entitlement to 
everybody to know any information collected about his 
or her health, including the right not to be so informed.
Convention on the Rights of the Child (UN 1998)
Article 33 states that all measures must be taken to protect 
children from the use of narcotic drugs and psychotropic 
substances.
Convention on the Rights of Persons with Disabilities 
(UN 2006)
This Convention includes principles of non-discrimination, 
right to health, rehabilitation, promotion of dignity of persons 
with disabilities through public awareness campaigns, the  right 
to adequate standard of living, etc. (Articles 4, 5, 8, 25-28).
▶
▶
▶
▶
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Supply reduction
UN Single Convention on Narcotic Drugs  
(UN 1961, amended 1972)
The Single Convention codified all existing multilateral treaties on 
drug control and extended the existing control systems to include 
the cultivation of plants that were grown as the raw material of 
narcotic drugs. The principal objectives of the Convention are 
to limit the possession, use, trade in, distribution, import, export, 
manufacture and production of drugs exclusively to medical 
and scientific purposes and to address drug trafficking through 
international cooperation to deter and discourage drug traffickers. 
The Convention also established the International Narcotics 
Control Board, merging the Permanent Central Board and the 
Drug Supervisory Board.
Convention on Laundering, Search, Seizure and 
Confiscation of the Proceeds from Crime  
(Council of Europe 1990)
This instrument tackles the issues of proceeds and assets 
generated from serious crime on a broad front and ensuring 
that logistical cells cannot find financial safe havens anywhere 
in Europe. It reinforces international cooperation in criminal law 
matters, including by way of provisions allowing information on 
holders of bank accounts and their transactions to be divulged. 
The possibility of extending these provisions to non bank financial 
institutions is also provided for.
Agreement on Illicit Traffic by Sea implementing Article 17 
of the United Nations Convention against Illicit Traffic in 
Narcotic Drugs and Psychotropic Substances  
(Council of Europe 1995)
The Agreement on the interdiction of vessels engaged in drug 
trafficking activities in international waters is an implementation 
instrument for the 1988 UN Convention. Particular attention 
is paid to developments relating to action against stateless 
vessels, measures taken at the request of the Flag State, and 
the central role accorded to the concept of preferential jurisdiction 
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in instances where law enforcement activities are initiated by 
one party with the prior consent of the Flag State. Other issues 
addressed range from the regulation of the use of force to the 
payment of compensation.
 
Law enforcement
Quasi coerced treatment  
(Pompidou Group P-PG/CJ (2010) 3)
An overview of national experiences with quasi-coerced treatment 
of drug dependent offenders. 
Quasi coerced treatment: findings from a survey conducted 
in PG member States (Pompidou Group P-PG-CJ (2008) 15)
Alternatives to imprisonment show to be more cost-effective 
and have fewer adverse effects. According to the evidence 
collected, ‘quasi-coerced’ treatment can be effective in reducing 
substance use, risk and offending behaviours, and improving 
social integration. It can be as effective as voluntary treatment, if 
received in the same treatment services.
Guidelines on the application of quasi coerced treatment 
(Pompidou Group P-PG-CJ (2007) 21)
The rationale for quasi-coerced treatment lies in the rising of the 
prison populations of which a large proportion is drug-related and 
in the relative ineffectiveness of other sanctions in deterring drug 
use and related crime.
Road Traffic and Psychoactive Substances  
(Pompidou Group 2004 – ISBN publication)
This publication takes stock of existing measures and policies 
dealing with road safety when driving under the influence of 
substances which adversely affect one’s ability to drive, including 
questions of prevalence and risk assessment, problems in the 
field of policy implementation , prevention and substitution 
treatment, as well as providing expert recommendations.
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Prevention of precursors diversion  
(Pompidou Group P-PG-CJ (2009) 2)
Conclusions and recommendations of an expert conference on 
the backtracking investigations, evidence collection, sanction 
and prevention of drug precursor diversion. 
Drug precursor diversion through efficient networking 
(Pompidou Group P-PG-Precursors (2010) 3) 
Conclusions and recommendations of an expert conference 
on the prevention of drug precursor diversion through efficient 
networking of agencies involved.
EU organised crime threat assessment (OCTA 2011) 
Conclusions and future strategic considerations for EU law 
enforcement agencies.
 
Prevention
Drug testing at school and in the workplace  
(Pompidou Group P-PG/Ethics (2008) 5)
Expert opinions and recommendations addressing ethical issues 
related to drug testing at school and at the workplace. 
Pompidou Group manual on outreach work  
(Pompidou Group P-PG/Prev (2003) 6)
This publication puts an emphasis on secondary prevention 
targeting young people, young drug users and young people at 
risk. It provides decision makers, professionals and practitioners 
with experience based guidance for implementing outreach work 
as a key component of any prevention strategy.  
Prevention interventions in recreational settings  
(Pompidou Group P-PG/Prev (2010) 7)
The publication aim is to assist local authorities across Europe 
in addressing the problems related to misuse of drugs in holiday 
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resorts, tourist towns and other recreational settings. The 
publication defines “drug misuse” broadly, to include alcohol 
and tobacco misuse. Special focus is on a recreational nightlife 
context within which drug misuse and related problems mostly 
arise.
Ethical questions raised by immunotherapy of addiction 
(Pompidou Group P-PG/Ethics (2010) 11)
At the example of the “vaccine” against cocaine this expert report 
and opinion looks into the ethical issues raised by  ‘vaccines’ 
against certain drugs and examined the ethical aspects linked to 
informed and conscious consent in medical research involving 
drug dependent persons and drug users.
Overview of projects submitted to the European Drug 
prevention Prize in 2004 – 2006 – 2008 – 2010 - Summary of 
prize-winning projects and shortlisted projects  
(Pompidou Group P-PG/PREV/PP (2010) 4)
Every two years, the Pompidou Group organises the European 
Drug Prevention Prize and receives a number of valuable and 
impressive active youth drug prevention projects. While only 
three European Drug Prevention Prizes are awarded, many other 
entries are recognised and therefore shortlisted. These may offer 
new and creative ideas and may serve as a resource for policy 
makers, researchers, experts, practitioners and even young 
people in the creation and development of their own projects and 
programmes
Evaluation of Drug Prevention Activities  
(Pompidou Group P-PG/Prev (2010) 6)
This study explores the limitations of evaluating drug prevention 
interventions and identifies ways that evaluation can be made 
more effective.
Prevention and Evaluation Resources Kit (EMCDDA 2010)
This manual compiles basic but evidence-based prevention 
principles, planning rules and evaluation tips. Additionally, it 
provides related documentation and references.
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Evaluation: a key tool for improving drug prevention 
(EMCDDA 2010)
This publication addresses the practical and political aspects 
of evaluation and presents an array of tools to improve drug 
prevention programmes.
Treatment
Treatment systems overview  
(Pompidou Group 2010– ISBN publication)
This publication presents an overview of the treatment systems 
of 22 of the 35 Pompidou Group member countries. It focuses 
on the emerging trend to cater for poly-drug us, a trend that is 
now emerging across Europe. The diversity of treatment systems 
reflects the complexity of the local legal, political, economic 
and cultural context of drug problems. This is a source of good 
practices for making treatment accessible and available. This 
overview is useful for policy makers and practitioners alike. 
Drug treatment demand data: Influence on policy and practice 
(Pompidou Group 2006- ISBN publication)
Three case studies describe how treatment demand data has 
been used in the development of drug policies and services in 
Ireland, Italy and Slovenia. One strong message coming out 
of this report is the need for more information on the outcome 
of treatment. Policy makers clearly need more information on 
patients at the end of their treatment, including information on 
further treatment and its effectiveness.
Drug Abuse Treatment and Rehabilitation (UNODC 2003) 
This toolkit provides a practical planning and implementation 
guide for decision makers and administrators.
Investing in Drug Abuse Treatment (UNODC 2003)
This discussion paper for policy makers concludes that substance 
abuse treatments can and should be expected to improve the 
public health and social problems of patients and that there 
are methods of organizing the structure and delivery of care to 
achieve those outcomes.
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Contemporary drug abuse treatment - A review of the 
Evidence Base (UNODC 2002)
This review presents a thematic summary of the research 
evidence base for the effectiveness and main influencing factors 
of contemporary drug abuse treatment. The review is designed to 
be a companion resource to the section on effective treatment and 
rehabilitation services in the publication “Drug abuse treatment 
and rehabilitation” and to the document entitled “Investing in drug 
abuse treatment”.
WHO, UNODC, UNAIDS Technical Guide (2009)
This is a guide for countries to set targets for universal access to 
HIV prevention, treatment and care
for injecting drug users.
Guidelines for the psychosocially assisted pharmacological 
treatment of opioid dependence (WHO 2009)
These guidelines were developed in response to a resolution from 
the United Nations Economic and Social Council (ECOSOC), which 
invited the World Health Organization (WHO), in collaboration 
with the United Nations Office on Drugs and Crime (UNODC), 
to develop and publish minimum requirements and international 
guidelines on psychosocially assisted pharmacological treatment 
of persons dependent on opioids. The guidelines are intended to 
be read by those involved in providing psychosocially assisted 
pharmacological treatments at any level. Psychosocially assisted 
pharmacological treatment refers to the combination of specific 
pharmacological and psychosocial measures used to reduce 
both illicit opioid use and harms related to opioid use and improve 
quality of life.
Position paper: substitution maintenance therapy in the 
management of opioid dependence and HIV prevention 
(WHO/UNODC/UNAIDS 2004)
The position paper sets out guiding principles for the practice of 
substitution maintenance therapy. 
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Assessment and evaluation 
	Determining the drug situation 
EMCDDA annual reports on the state of the drugs problem 
in Europe
The EMCDDA reports on the state of the drugs problem in Europe 
present the EMCDDA’s yearly overview of the drug phenomenon. 
This is an essential reference book for policymakers, specialists 
and practitioners in the drugs field or indeed anyone seeking the 
latest findings on drugs in Europe. Published every autumn, the 
report contains non-confidential data supported by an extensive 
range of figures.
ESPAD Reports
The reports of the European School Survey Project on Alcohol 
and other Drugs (ESPAD) are based on Data collections from the 
ESPAD project which are held every fourth year in participating 
countries. Apart from the international reports there are a number 
of national reports as well as articles and papers published, using 
data from the ESPAD project. 
Drug Abuse Rapid Situation Assessment and Responses 
(UNODC 1999) 
Rapid assessments are used to help make decisions about the 
kinds of interventions that are required. Interventions may be 
inappropriate unless developed from a proper assessment of the 
situation. Rapid assessments can identify the appropriateness 
and feasibility of proposed interventions as well as obstacles and 
possible ways around them. 
Technical Guide to Rapid Assessment and Response (WHO 
2001 TG-RAR)
The Technical Guide to Rapid Assessment and Response 
provides a detailed introduction into all aspects of planning 
and implementing rapid situation assessments. It is generic in 
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nature and can be used for a variety of health issues. TG-RAR 
is best used in conjunction with Adaptation Guides, providing 
brief guidance on how to use the RAR approach with regard to a 
specific health issue.
Rapid Assessment of Alcohol and other Substance Use in 
Conflict-affected and Displaced Populations: A Field Guide 
(WHO and UNHCR 2008) 
An increase in alcohol and other substance use is among the many 
health and social issues associated with conflict and displacement. 
Problems with substance use are prevalent in a variety of conflict 
affected situations including camps for and communities of 
refugees. Rapid assessment methods can be used to quickly gather 
information on substance use in an identified area or community. 
	Determining the state and quality of preventive 
interventions 
Evaluating drug prevention in the European Union 
(EMCDDA 1998)
An overview on different prevention philosophies and arguments 
for making evaluation a routine and scientifically sound procedure 
that draws on good practice and proven methodology.
Technical Consultation on the Assessment of Prevention 
and Treatment Systems for Substance Use Disorders (WHO 
2006)
The report examines methods and technologies for assessing, 
monitoring, and evaluating prevention and treatment systems 
for substance use disorders, in relation to population needs and 
proposes an instrument to aid in this analysis for development.
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	Determining the state and quality of therapeutic 
services 
Schedules for the assessment of standards of care (WHO 
1993 – ASC 1-5)
Assessing services for meeting the WHO standards of availability, 
accessibility, assessment procedures, treatment provision, 
aftercare & referral, patient’s rights.
Quality assurance in mental health care (WHO 1994, 
adapted for substance abuse 2009)
Instrument developed for checking the quality of the physical 
environment, administrative arrangements and networking of 
services.
International guidelines for psychosocially assisted 
pharmacological treatment of opioid dependence (WHO 
2008)
Evidence based guidelines for detoxification and maintenance 
treatments with detailed recommendations and a checklist for 
minimal standards.
• Determining the state and quality of harm 
reduction services 
Harm Reduction: evidence, impact and challenges 
(EMCDDA 2010) 
This monograph provides a comprehensive overview of the 
harm reduction field. Part I of the monograph looks back at the 
emergence of harm reduction approaches and their spread 
across Europe. Part II is dedicated to current evidence and 
impact of harm reduction measures. Part III addresses the current 
challenges and innovations in the field. 
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Assessment instrument for harm reduction interventions 
(EMCDDA 2009)
This best practice portal by EMCDDA provides pooled results or 
narrative conclusions from studies of specific interventions, as 
well as detailed information on methodology and definitions.
• Determining outcomes and impact of 
interventions
Evaluation of the European Union’s 2000–04 drug strategy 
and drug action plan (EMCDDA 2004)
For the first time the EU drug strategy was evaluated in terms 
of its implementation in member States. The report provides 
information on the progress achieved between the beginning and 
end of the action plan, as well as on efforts yet to be made.
Addiction Severity Index (6th version, adapted for Europe)
Instrument for measuring substance use, health, social situation 
and criminal involvement of patients before and after treatment.
Quality of life questionnaire, short version (WHOQOL-BREF)
A tool for rating the patient’s subjective quality of life before and 
after treatment.
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Work in progress
European drug prevention quality standards  
(EMCDDA, 2011 - ) 
The EMCDDA is currently collaborating in an EU-funded research 
project aimed at producing commonly agreed and evidence-
based drug prevention standards for use in the EU. It is hoped 
that these standards will be adopted by member States to improve 
drug prevention practice and efficiency of funding, and reduce the 
likelihood of ineffective or iatrogenic interventions.
Assessment of Prevention and Treatment Systems for 
Substance Use Disorders (WHO 2006 - )
The overall purpose of the Substance Abuse Instrument for 
Mapping Services WHO-SAIMS is to provide information on 
prevention and treatment systems to decision-makers so that 
information can be used for policy planning, service design and 
service improvement.
Evaluating national drug strategies and action plans 
(EMCDDA 2010 – 2012)
The EU Drugs Action Plan 2009–2012 stipulates to develop 
analytical instruments to better assess the effectiveness and 
impact of drug policy and requires member states to evaluate and 
fine-tune national drug policies on a regular or ongoing basis. The 
EMCDDA is starting to address these issues within its 2010 work 
programme with the aim to develop European guidelines for the 
evaluation of national drug strategies.
EU minimal quality standards for drug demand reduction 
(work in progress DG-JLS 2010-2011)
By 2012, the European Commission plans to submit to the Council 
a proposal for an EU Consensus on minimum quality standards 
and benchmarks in drug demand reduction. The proposal aims 
to contribute to a measurable improvement of minimum quality 
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standards and benchmarks covering all components in the field 
of drug demand reduction: prevention, treatment, harm reduction 
and rehabilitation & reintegration in the EU Member States.
WHO Substance Abuse Intervention Mapping System 
SAIMS (2008 - )
The aim of this project is to close the gap between what is needed 
and what is currently available to reduce the burden of disorders 
related to substances abuse. Information made available in 
regular reports can be used to strengthen mental health care 
systems which will result in better care and services to individuals 
and communities.
Treatnet project to support capacity building and good 
practice worldwide (UNODC since 2006)
Treatnet is a UNODC initiated and supported network  that aims 
to promote and support evidence-based and ethical treatment 
policies for substance use and abuse through diversified, effective 
and quality drug dependence treatment and rehabilitation 
services, including HIV/AIDS prevention and care.
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Observations on 
practical experiences 
from drug policies 
2003 and 2010
Based on a range of signals and conclusions from the different 
sectors of work in the Pompidou Group between 2003 and 2010 
the Permanent Correspondents of member States governments 
identified the following observations as of particular concern and 
relevance to drug policy makers (docs. P-PG /MinConf (2010) 1) 
and P-PG/MinConf (2006) 1):
Linking policy and research: It needs to be recalled that policy 
responses to drugs and drug-related problems cannot only be 
based on scientific evidence and vigour, but also need to take 
into account cultural influences, organisational structures and 
public opinion. It has to be noted that research results apparently 
seldom influence drug policy. Research results are frequently 
used, often in a selective and over-simplified way interpreted by 
political interest groups, in political debate in support of specific 
positions to which they correspond.
Human Rights: Including a human rights dimension in drug policies 
will help to underline the multidimensional nature of psychoactive 
substance use and addictions in terms of a range of inter-related 
and mutually reinforcing societal factors. Furthermore, the human 
2 Appendix
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rights dimension would allow this aspect to be brought back to 
centre stage. Adding a human rights dimension to the evidence 
based approaches can help to refocus drugs policies on demand 
reduction and thus bring public health, as the first principle of drug 
control policies, back to the forefront.
Broad evidence base:  With fundamental values serving as 
a starting point, evidence based policies can  facilitate the 
development of timely and targeted responses to the multi-
faceted and fast evolving problems that relate to drug use, and 
it is important to establish priorities and guidelines for the public 
funding of research institutions accordingly.   Policy making 
on drug use should take into consideration not only evidence 
from research and experience from practice, but also concerns 
about the wider implications of policies. And simple reliance on 
empirical data when taking policy decisions will not be sufficient. 
Data quality, compatibility of statistics, and causal relations, 
must also be taken into account.  Existing statistics need to be 
combined with interpretations from multidisciplinary perspectives, 
to be complemented by qualitative research and to be verified 
by professional experience. A strategy of this kind is more likely 
to unlock ‘hidden knowledge’ in existing data to be exploited in 
current and future research. Without investment in high quality 
data analysis the investment in statistics does not yield a valuable 
return.
Complexity: Given the complexity of the problems that societies 
face in relation to drug use, it is crucial that a multidisciplinary 
approach be adopted. This will require co-operative action across 
sectors and disciplines and will involve a variety of relevant 
agencies and stakeholders. Only such intersectoral action can 
take into account the different dimension of a specific problem 
and properly ensure the effectiveness of policies and the efficient 
use of resources.
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Coherence: The aims of multisectoral co-operation must be 
inspired and guided by policy-makers. It is consequently of 
importance that the political concepts and messages of policy 
makers on the one hand are coherent with the messages of 
the different actors working in the field, on the other – not only 
when new policies are first implemented but also as their effects 
become known.
Analysis: Skills, tools and resources to evaluate the effect and 
impact of interventions need to be developed.  This will require 
the strengthening of an evaluation culture in drugs programmes 
across Europe. A current challenge is to understand the extent 
to which drug use and drug users are influenced by drug policy. 
Understanding this requires research on the policy-making 
process itself and its consequences, in particular to identify and 
separate out intended and unintended outcomes and effects.
Realism: The setting of unrealistic success indicators can frustrate 
policy approaches and constitute an obstacle in establishing what 
actually works and has an impact. Successful policies must have 
realistic expectations and verifiable results. Outcomes need to be 
measurable to allow for proper implementation, management and 
assessment. For example, policy makers should be aware that 
there is currently no pedagogic evidence on the effectiveness of 
drug testing in schools as a means of preventing drug use and 
abuse. In cases where drug testing in schools is considered, all 
relevant pedagogical and legal issues, in particular ethics and 
human rights related questions, need to be taken into account.
Balance: The vast weight of evidence favours the balanced 
approach in supply and demand reduction policies. A tendency 
to invest more in supply reduction policies can be observed on 
some levels. It needs to be borne in mind, however, that despite 
new technologies and changing patterns of drug smuggling, 
only balanced policies addressing all relevant can be effective in 
tackling the problems related to illicit drugs.  
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Experimentation: Producing an evidence base for policy making 
has limitations in a multifaceted field such as drugs policies, since 
it is often difficult to establish causal relationships. It is thus equally 
viable to consider science and knowledge based approaches, for 
example. However it is important that these approaches do not 
stifle innovation and block the path for innovative policies.  Of 
course, such innovative policies must accord with the international 
drug control system as enshrined in the UN Conventions. Within 
this framework, however, experimentation and unconventional 
approaches can help to develop new solutions and overcome 
existing barriers to effective policies.
Informed choices: The issue of informed choices is crucial to 
all decisions in connection with adopting policies, implementing 
interventions and deciding on drugs research. Choices to be 
made constitute critical factors in legislative decisions, legal 
determinations as well as personal choices. Being based on 
the notion of individual free will, the concept of informed choice 
has to be constantly reviewed in the light of emerging results 
from neurosciences and genetics as to what conditions human 
behaviour. 
Supply reduction: To stop the production of synthetic drugs, 
early intervention at the beginning of the drug production chain 
is crucial. Special attention is given to the potential risk of airport 
personnel involved in drug trafficking. This type of crime can only 
be kept in check by a harmonised, international, multi-agency 
approach. In addition, new forms of co-operation with authorised 
private companies present at the airports are necessary to stay in 
control of airport crime risks.
Drug user registration: Registration systems for drug users 
require urgent reform since systems of patient registration are 
an important source of information for developing target group 
oriented treatment options.  When setting up registration systems, 
due attention has to be paid to safeguarding clients’ data. If 
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adequate data protection cannot be attained and demonstrated 
registration of drug users can constitute a barrier for people in 
need to seek treatment for fear of negative consequences. 
Treatment systems: Drug treatment in European countries 
should be based on scientific evidence and good practice 
rather than on tradition, belief and unrealistic expectations. The 
perspectives of drug users, their relatives and others affected by 
the drug use and associated problems receive little attention. This 
can constitute a serious obstacle to the provision of adequate 
and successful treatment. Monitoring the application of treatment 
options and taking into account drug research results will provide 
information on what works and what impact is achieved. 
Chronic condition: Drug abuse is often a long-term problem 
for individuals, and addiction constitutes a chronic disease. In 
previous years, this has regularly been underestimated. As a 
result, in many cases intervention concepts and related resource 
planning are placed in a short and medium term perspective 
based on a vague hope of cure and social re-integration. In 
order to be effective, time scales for interventions and services 
rendered must be readjusted to such realities. Proceeding from 
this, policies and services must also take into account that there 
will be a growing number of older drug users for whom adequate 
medical and social responses will have to be developed.
Co-operation: Partnerships between stakeholders at frontline 
level do not provide all the solutions to drug problems, but it can be 
more effective and resource-efficient than traditional approaches 
to implement such policies. An integrated approach combining law 
enforcement, treatment and prevention can improve the impact 
of drug policies. A prerequisite for implementing such integrated 
policies is the ability of the relevant stakeholders to co-operate in 
partnerships at first-line level.
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Communication between stakeholders: Clarification and 
definition of the role, position, responsibilities of stakeholders in 
the drugs field, better to coordinate research, policy making and 
professional action, is needed to develop more effective policies. 
Policy makers need to request clear and specific guidance from 
research and practice to develop timely policy responses to issues 
of pressing importance. At the same time policy makers have to be 
aware that the full effect and sustainability of responses can only 
be assured if medium and long-term back-up policies are adopted 
and resourced. Research and practice need to understand better, 
and to incorporate into their work, the legitimate demands from 
the public and from policy makers to deliver results in reasonable 
time with clear and precise indications on required action 
and realistically anticipated results. Better synergy between 
stakeholders can help to avoid overlap and duplication at national 
and European level. 
Participation: Active youth participation and involvement in 
drugs prevention is a reality across Europe and should be at the 
heart of drug prevention policies. Youth participation brings added 
value to efforts of governments and civil society in tackling drugs-
related issues, because it has the potential to reinforce protective 
factors whilst impacting on risk behaviour.
Virtual tools: The use of information and communication 
technology provides added value to reduce drug abuse and 
addictions, if it becomes an interactive tool that links users with 
the professionals and agencies tasked to deal with drug-related 
problems. Whether information technology will play a positive 
role in diverting young people from substance use, or conversely 
be used as a means to promote it, will depend on support for 
young people in the development of their ability  to deal with 
this adequately. Recognition of their capacities, resources and 
energy will determine the positive role they can play in reducing 
or preventing drug use.
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Assessment: Evaluation requires further expansion and 
application in Europe. It should be understood that it is first of 
all an instrument for measuring impact and making practical 
improvements. When reduced to a tool for convincing funders or 
lobbying for resources, the scope and purpose of intervention will 
be distorted and consequently the usefulness of the assessment 
results will diminish.
Capacity building: The Pompidou Group has demonstrated in 
a wide range of activities, including MedNET co-operation and 
the Life Skills Training Programmes, its ability to contribute to the 
shaping and implementation of different interventions, as well 
as to the preparation of strategies and actions. In this way the 
Group’s work can have demonstrable impact on drug policies. 
This can be a unique complementary contribution to EU action 
under its Neighbourhood Policy and related programmes, as 
potential to be borne in mind and utilised by decision makers 
wherever appropriate to support non-EU States in developing 
drug strategies and policies.  


